A tipping point in cancer-immune dynamics leads to divergent immunotherapy responses and hampers biomarker discovery
View ORCID ProfileJeroen H.A. Creemers, View ORCID ProfileWillem J. Lesterhuis, View ORCID ProfileNiven Mehra, View ORCID ProfileWinald R. Gerritsen, View ORCID ProfileCarl G. Figdor, View ORCID ProfileI. Jolanda M. de Vries, View ORCID ProfileJohannes Textor
doi: https://doi.org/10.1101/2020.10.29.20222455
Jeroen H.A. Creemers
1Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences; Radboudumc, Nijmegen, The Netherlands
4Oncode Institute, Nijmegen, The Netherlands
Willem J. Lesterhuis
3School of Biomedical Sciences and Telethon Kids Institute, University of Western Australia, Perth, Australia
Niven Mehra
2Department of Medical Oncology, Radboudumc, Nijmegen, The Netherlands
Winald R. Gerritsen
2Department of Medical Oncology, Radboudumc, Nijmegen, The Netherlands
Carl G. Figdor
1Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences; Radboudumc, Nijmegen, The Netherlands
4Oncode Institute, Nijmegen, The Netherlands
I. Jolanda M. de Vries
1Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences; Radboudumc, Nijmegen, The Netherlands
Johannes Textor
1Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences; Radboudumc, Nijmegen, The Netherlands
5Data Science Department, Institute for Computing and Information Sciences, Radboud University, Nijmegen, The Netherlands
Data Availability
The code of the ODE model is available at GitHub.
https://github.com/jeroencreemers/tipping-point-cancer-immune-dynamics.
Posted November 03, 2020.
A tipping point in cancer-immune dynamics leads to divergent immunotherapy responses and hampers biomarker discovery
Jeroen H.A. Creemers, Willem J. Lesterhuis, Niven Mehra, Winald R. Gerritsen, Carl G. Figdor, I. Jolanda M. de Vries, Johannes Textor
medRxiv 2020.10.29.20222455; doi: https://doi.org/10.1101/2020.10.29.20222455
A tipping point in cancer-immune dynamics leads to divergent immunotherapy responses and hampers biomarker discovery
Jeroen H.A. Creemers, Willem J. Lesterhuis, Niven Mehra, Winald R. Gerritsen, Carl G. Figdor, I. Jolanda M. de Vries, Johannes Textor
medRxiv 2020.10.29.20222455; doi: https://doi.org/10.1101/2020.10.29.20222455
Subject Area
Subject Areas
- Addiction Medicine (357)
- Allergy and Immunology (680)
- Anesthesia (182)
- Cardiovascular Medicine (2693)
- Dermatology (229)
- Emergency Medicine (405)
- Epidemiology (12330)
- Forensic Medicine (10)
- Gastroenterology (772)
- Genetic and Genomic Medicine (4166)
- Geriatric Medicine (392)
- Health Economics (689)
- Health Informatics (2703)
- Health Policy (1010)
- Hematology (366)
- HIV/AIDS (864)
- Medical Education (401)
- Medical Ethics (110)
- Nephrology (446)
- Neurology (3949)
- Nursing (214)
- Nutrition (587)
- Oncology (2083)
- Ophthalmology (596)
- Orthopedics (245)
- Otolaryngology (308)
- Pain Medicine (253)
- Palliative Medicine (75)
- Pathology (474)
- Pediatrics (1134)
- Primary Care Research (462)
- Public and Global Health (6591)
- Radiology and Imaging (1429)
- Respiratory Medicine (879)
- Rheumatology (415)
- Sports Medicine (345)
- Surgery (456)
- Toxicology (55)
- Transplantation (191)
- Urology (170)